The Journal of Practical Medicine >
Analysis of risk factors for pegaspargase⁃associated acute pancreatitis in childhood with B⁃cell acute lymphoblastic leukemia
Received date: 2025-04-28
Online published: 2025-09-25
Objective To analyze the clinical characteristics and risk factors of children with B-cell acute lymphoblastic leukemia （B-ALL） who developed acute pancreatitis （AP） after treatment with pegaspargase （PEG-ASP）. Methods A retrospective analysis was conducted on the general data， clinical data， blood routine data， albumin concentration， and cumulative dose of PEG-ASP of 272 children with ALL complicated with AP who received PEG-ASP treatment in the hospital from January 2021 to February 2023. The correlations between gender， age， risk stratification， cumulative dose of pegaspargase， blood routine indicators， albumin concentration and the progression of pancreatitis were analyzed. Results Among the 272 children， the incidence of AP was 8.5% （23/272）. There was no statistically significant correlation between AP and gender， age， body mass index （BMI）， risk stratification， cumulative dose of pegaspargase， hemoglobin concentration， platelet count and monocyte count （P > 0.05）， but there was a significant correlation with white blood cell count， neutrophil count， lymphocyte count， neutrophil/lymphocyte ratio， platelet/lymphocyte ratio and albumin concentration （P < 0.05）. Logistic regression analysis further showed that white blood cell count， neutrophil count， lymphocyte count and albumin concentration were related to the occurrence of PEG-ASP-related AP （P < 0.05）. ROC analysis found that white blood cell count， lymphocyte count and albumin concentration could predict the occurrence of PEG-ASP-related AP. Conclusions White blood cell count， neutrophil count， lymphocyte count and albumin concentration are risk factors for PEG-ASP-related AP in children with B-ALL. Especially， abnormal white blood cell count， lymphocyte count and albumin concentration in blood routine examination can help identify high-risk children with B-ALL complicated with PEG-ASP-related AP at an early stage.
Xiaozhen JIANG , Xiuxian CHEN , Wenming LI . Analysis of risk factors for pegaspargase⁃associated acute pancreatitis in childhood with B⁃cell acute lymphoblastic leukemia[J]. The Journal of Practical Medicine, 2025 , 41(18) : 2853 -2858 . DOI: 10.3969/j.issn.1006-5725.2025.18.010
| [1] | MALARD F， MOHTY M. Acute lymphoblastic leukaemia［J］. Lancet， 2020，395（10230）： 1146-1162. doi:10.1016/s0140-6736(19)33018-1 |
| [2] | LEE M， HAMILTON J A G， TALEKAR G R， et al. Obesity-induced galectin-9 is a therapeutic target in B-cell acute lymphoblastic leukemia［J］. Nat Commun， 2022，13（1）： 1157. doi:10.1038/s41467-022-28839-y |
| [3] | 强晓， 耿贝贝， 刘四喜， 等. 转录组学技术在急性白血病诊治中的应用研究进展［J］. 实用医学杂志， 2023，39（22）： 3010-3014. doi:10.3969/j.issn.1006-5725.2023.22.027 |
| [4] | FANG H， WANG W， MEDEIROS L J. Burkitt lymphoma［J］. Hum Pathol， 2025，156： 105703. doi:10.1016/j.humpath.2024.105703 |
| [5] | J?DRASZEK K， MALCZEWSKA M， PARYSEK-WóJCIK K， et al. Resistance Mechanisms in Pediatric B-Cell Acute Lymphoblastic Leukemia［J］. Int J Mol Sci， 2022，23（6）：3067. doi:10.3390/ijms23063067 |
| [6] | TEACHEY D T， DEVIDAS M， WOOD B L， et al. Children's Oncology Group Trial AALL1231： A Phase Ⅲ Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma［J］. J Clin Oncol， 2022，40（19）： 2106-2118. doi:10.1200/jco.21.02678 |
| [7] | HAYASHI R J， WINTER S S， DUNSMORE K P， et al. Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma： Results From Children's Oncology Group AALL0434［J］. J Clin Oncol， 2020，38（26）： 3062-3070. doi:10.1200/jco.20.00531 |
| [8] | VROOMAN L M， BLONQUIST T M， STEVENSON K E， et al. Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia： Results of DFCI 11-001［J］. J Clin Oncol， 2021，39（31）： 3496-3505. doi:10.1200/jco.20.03692 |
| [9] | CHEN C， LI J， CHEN Y， et al. The correlation of asparaginase enzyme activity levels after PEG-asparaginase administration with clinical characteristics and adverse effects in Chinese paediatric patients with acute lymphoblastic leukaemia［J］. Br J Haematol， 2024，205（2）： 624-633. doi:10.1111/bjh.19605 |
| [10] | WANG J， SHEN S， HU B， et al. Successful use of trametinib and dasatinib combined with chemotherapy in the treatment of Ph-positive B-cell acute lymphoblastic leukemia： A case report［J］. Medicine （Baltimore）， 2021，100（25）： e26440. doi:10.1097/md.0000000000026440 |
| [11] | LYNGGAARD L S， RANK C U， ALS-NIELSEN B， et al. PEG-asparaginase treatment regimens for acute lymphoblastic leukaemia in children： A network meta-analysis［J］. Cochrane Database Syst Rev， 2023， 5（5）： CD14570. doi:10.1002/14651858.cd014570.pub2 |
| [12] | WU J， CHEN C， HUANG S， et al. Correlation of L-asp Activity， Anti-L-asp Antibody， Asn and Gln With Adverse Events Especially Anaphylaxis Risks in PEG-asp-Contained Regime Treated Pediatric ALL Patients［J］. Technol Cancer Res Treat， 2020，19： 1079247761. doi:10.1177/1533033820980113 |
| [13] | HOSHITSUKI K， ZHOU Y， MILLER A M， et al. Rituximab administration in pediatric patients with newly diagnosed acute lymphoblastic leukemia［J］. Leukemia， 2023，37（9）： 1782-1791. doi:10.1038/s41375-023-01992-z |
| [14] | 中华医学会儿科学分会血液学组， 编辑委员会中华儿科杂志. 儿童急性淋巴细胞白血病诊疗建议（第四次修订）［J］. 中华儿科杂志， 2014， 52（9）： 641-644. |
| [15] | WALL J M. Clinical Guideline Highlights for the Hospitalist： Management of Acute Pancreatitis in the Pediatric Population［J］. J Hosp Med， 2019，14（12）： 762-763. doi:10.12788/hm.3285 |
| [16] | LI X， ZHANG Y， MIXDORF J C， et al. Development and Preclinical Evaluation of ［（64）Cu］Cu-NOTA-ABDB6： A CD70 and Albumin Dual-Binding Tracer with Improved Pharmacokinetics［J］. J Nucl Med， 2025，66（4）： 552-558. doi:10.2967/jnumed.124.268835 |
| [17] | RAHIMAN E A， BAKHSHI S， DEEPAM P， et al. Outcome and prognostic factors in childhood B non-Hodgkin lymphoma from India： Report by the Indian Pediatric Oncology Group （InPOG-NHL-16-01 study）［J］. Pediatr Hematol Oncol， 2022，39（5）： 391-405. doi:10.1080/08880018.2021.2002485 |
| [18] | THOMAS S， MAHAPATRA M， SETH T， et al. Evaluation of Nutritional Status During Induction Chemotherapy in Patients With Acute Leukemia［J］. Cureus， 2025，17（5）： e83547. |
| [19] | LIBBUS I， NEARING B D， AMURTHUR B， et al. Quantitative evaluation of heartbeat interval time series using Poincaré analysis reveals distinct patterns of heart rate dynamics during cycles of vagus nerve stimulation in patients with heart failure［J］. J Electrocardiol， 2017，50（6）： 898-903. doi:10.1016/j.jelectrocard.2017.06.007 |
| [20] | DUNSMORE K P， WINTER S S， DEVIDAS M， et al. Children's Oncology Group AALL0434： A Phase Ⅲ Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia［J］. J Clin Oncol， 2020，38（28）： 3282-3293. doi:10.1200/jco.20.00256 |
| [21] | MESEGUé M， ALONSO-SALADRIGUES A， PéREZ-JAUME S， et al. Lower incidence of clinical allergy with PEG-asparaginase upfront versus the sequential use of native E. coli asparaginase followed by PEG-ASP in pediatric patients with acute lymphoblastic leukemia［J］. Hematol Oncol， 2021，39（5）： 687-696. |
| [22] | CUI J， JIANG L， XU B， et al. L-asparaginase activity and anti-L-asparaginase antibody as biomarkers in estimating PEG-asp-related anaphylaxis risk in childhood acute lymphoblastic leukemia patients［J］. Allergol Immunopathol （Madr）， 2023，51（3）： 28-35. doi:10.15586/aei.v51i3.771 |
| [23] | MATTANO L A J， DEVIDAS M， MALONEY K W， et al. Favorable Trisomies and ETV6-RUNX1 Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia： Results From Children's Oncology Group Trial AALL0331［J］. J Clin Oncol， 2021，39（14）： 1540-1552. doi:10.1200/jco.20.02370 |
| [24] | LIU C， YANG W， DEVIDAS M， et al. Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia［J］. J Clin Oncol， 2016，34（18）： 2133-2140. doi:10.1200/jco.2015.64.5812 |
| [25] | 许乐乐， 陈彦君， 陆件， 等. 基于肠道生物标志物评价肠内营养补充益生菌治疗重症胰腺炎的获益与限制［J］. 实用医学杂志， 2024，40（24）： 3458-3467. |
| [26] | 赖肖蓉. 培门冬酶诱发儿童急性胰腺炎的危险因素及其严重程度预测分析［D］. 广州： 南方医科大学， 2024. doi:10.3760/cma.j.cn101070-20230602-00440 |
/
| 〈 |
|
〉 |